Introduction

This page provides a comprehensive analysis of the known insider trading history of David Kirske. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate David Kirske has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:US98420X1110 / X4 PHARMACEUTICALS INC WARRANTS EXP 4/12/24 0.00000000 Chief Financial Officer 193,254
US:CTIC / CTI BioPharma Corp EVP, Chief Financial Officer 0
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by David Kirske. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Trading History

This table shows the complete list of insider trades made by David Kirske as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2025-08-14 2025-08-14 4 XFOR X4 Pharmaceuticals, Inc
Common Stock
A - Award 193,254 193,254
2023-06-26 2023-06-26 4 CTIC CTI BIOPHARMA CORP
Common Stock
U - Other -17,547 0 -100.00 9.10 -159,678
2023-01-03 2023-01-03 4 CTIC CTI BIOPHARMA CORP
common stock
S - Sale X -27,021 17,127 -61.21 6.01 -162,423 102,950
2023-01-03 2023-01-03 4 CTIC CTI BIOPHARMA CORP
common stock
M - Exercise 27,021 44,148 157.77 0.95 25,640 41,892
2023-01-03 2022-12-30 4 CTIC CTI BIOPHARMA CORP
common stock
S - Sale X -1,047 17,127 -5.76 6.01 -6,292 102,933
2023-01-03 2022-12-30 4 CTIC CTI BIOPHARMA CORP
common stock
M - Exercise 1,047 18,174 6.11 0.95 993 17,245
2023-01-03 2022-12-30 4 CTIC CTI BIOPHARMA CORP
common stock
S - Sale X -800 17,127 -4.46 6.00 -4,804 102,848
2023-01-03 2022-12-30 4 CTIC CTI BIOPHARMA CORP
common stock
M - Exercise 800 17,927 4.67 0.95 759 17,011
2023-01-03 2022-12-30 4 CTIC CTI BIOPHARMA CORP
common stock
S - Sale X -12,000 17,127 -41.20 6.00 -72,000 102,762
2023-01-03 2022-12-30 4 CTIC CTI BIOPHARMA CORP
common stock
M - Exercise 12,000 29,127 70.06 0.95 11,387 27,639
2023-01-03 2022-12-30 4 CTIC CTI BIOPHARMA CORP
common stock
A - Award 214 17,127 1.27 5.11 1,093 87,493
2023-01-03 2022-12-29 4 CTIC CTI BIOPHARMA CORP
common stock
S - Sale X -13,174 16,913 -43.79 6.00 -79,044 101,478
2023-01-03 2022-12-29 4 CTIC CTI BIOPHARMA CORP
common stock
M - Exercise 13,174 30,087 77.89 0.95 12,501 28,550
2022-10-06 2022-10-04 4 CTIC CTI BIOPHARMA CORP
common stock
S - Sale X -609 16,913 -3.48 6.27 -3,818 106,045
2022-10-06 2022-10-04 4 CTIC CTI BIOPHARMA CORP
common stock
M - Exercise 609 17,522 3.60 0.95 578 16,627
2022-10-06 2022-10-04 4 CTIC CTI BIOPHARMA CORP
common stock
S - Sale X -100 16,913 -0.59 6.26 -626 105,875
2022-10-06 2022-10-04 4 CTIC CTI BIOPHARMA CORP
common stock
M - Exercise 100 17,013 0.59 0.95 95 16,144
2022-10-06 2022-10-04 4 CTIC CTI BIOPHARMA CORP
common stock
S - Sale X -1,400 16,913 -7.64 6.25 -8,750 105,706
2022-10-06 2022-10-04 4 CTIC CTI BIOPHARMA CORP
common stock
M - Exercise 1,400 18,313 8.28 0.95 1,328 17,377
2022-10-03 2022-10-03 4 CTIC CTI BIOPHARMA CORP
common stock
S - Sale X -300 16,913 -1.74 6.25 -1,875 105,706
2022-10-03 2022-10-03 4 CTIC CTI BIOPHARMA CORP
common stock
M - Exercise 300 17,213 1.77 0.95 285 16,333
2022-10-03 2022-09-30 4 CTIC CTI BIOPHARMA CORP
common stock
S - Sale X -139,841 16,913 -89.21 6.05 -845,549 102,264
2022-10-03 2022-09-30 4 CTIC CTI BIOPHARMA CORP
common stock
M - Exercise 139,841 156,754 826.83 0.95 132,695 148,744
2022-10-03 2022-09-29 4 CTIC CTI BIOPHARMA CORP
common stock
S - Sale X -100 16,913 -0.59 6.01 -601 101,647
2022-10-03 2022-09-29 4 CTIC CTI BIOPHARMA CORP
common stock
M - Exercise 100 17,013 0.59 0.95 95 16,144
2022-10-03 2022-09-29 4 CTIC CTI BIOPHARMA CORP
common stock
S - Sale X -800 16,913 -4.52 6.00 -4,800 101,478
2022-10-03 2022-09-29 4 CTIC CTI BIOPHARMA CORP
common stock
M - Exercise 800 17,713 4.73 0.95 759 16,808
2022-09-20 2022-09-16 4 CTIC CTI BIOPHARMA CORP
common stock
S - Sale X -22,592 16,913 -57.19 6.02 -136,004 101,816
2022-09-20 2022-09-16 4 CTIC CTI BIOPHARMA CORP
common stock
M - Exercise 22,592 39,505 133.58 0.95 21,438 37,486
2022-09-20 2022-06-30 4 CTIC CTI BIOPHARMA CORP
common stock
A - Award 9,516 16,913 128.65 2.12 20,141 35,796
2022-06-17 2022-06-17 4 CTIC CTI BIOPHARMA CORP
common stock
S - Sale X -50,000 7,397 -87.11 6.25 -312,505 46,232
2022-06-17 2022-06-17 4 CTIC CTI BIOPHARMA CORP
common stock
M - Exercise 50,000 57,397 675.95 3.30 165,000 189,410
2022-06-17 2022-06-17 4 CTIC CTI BIOPHARMA CORP
common stock
S - Sale X -10,000 7,397 -57.48 6.00 -60,000 44,382
2022-06-17 2022-06-17 4 CTIC CTI BIOPHARMA CORP
common stock
M - Exercise 10,000 17,397 135.19 1.00 10,000 17,397
2022-06-16 2022-06-14 4 CTIC CTI BIOPHARMA CORP
common stock
S - Sale X -10,000 7,397 -57.48 5.50 -55,000 40,684
2022-06-16 2022-06-14 4 CTIC CTI BIOPHARMA CORP
common stock
M - Exercise 10,000 17,397 135.19 0.95 9,489 16,508
2022-03-11 2022-03-09 4 CTIC CTI BIOPHARMA CORP
Stock Option (right to buy)
A - Award 280,000 280,000
2022-03-11 2021-12-31 4 CTIC CTI BIOPHARMA CORP
Common Stock
A - Award 1,817 7,397 32.56 2.11 3,830 15,593
2022-03-11 2021-06-30 4 CTIC CTI BIOPHARMA CORP
Common Stock
A - Award 1,782 5,580 46.92 2.12 3,787 11,858
2021-03-12 2021-03-10 4 CTIC CTI BIOPHARMA CORP
Stock Option (right to buy)
S - Sale 200,000 200,000
2021-03-12 2020-07-01 4 CTIC CTI BIOPHARMA CORP
Common Stock
A - Award 3,798 3,798 0.98 3,722 3,722
2020-03-13 2020-03-11 4 CTIC CTI BIOPHARMA CORP
Non-qualified Stock Option
A - Award 350,000 350,000
2019-02-21 2019-02-19 4 ctic CTI BIOPHARMA CORP
Non-Qualified Stock Option (right to buy)
A - Award 500,000 500,000
2018-09-20 2018-09-18 4 ctic CTI BIOPHARMA CORP
Non-Qualified Stock Option (right to buy)
A - Award 125,000 125,000
2018-05-17 2018-05-16 4 ctic CTI BIOPHARMA CORP
Non-Qualified Stock Option (right to buy)
A - Award 83,396 83,396
2017-10-19 2017-08-31 4/A ctic CTI BIOPHARMA CORP
Non-Qualified Stock Option (right to buy)
A - Award 25,000 25,000
2017-10-03 2017-09-29 4 ctic CTI BIOPHARMA CORP
Non-Qualified Stock Option (right to buy)
A - Award 315,000 315,000
2017-08-03 2017-08-01 4 CTIC CTI BIOPHARMA CORP
Stock Option (Right to Buy)
A - Award 25,000 25,000
2017-08-03 3 CTIC CTI BIOPHARMA CORP
Common Stock, no par value per share
0
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)